Wire · operational-macro
AZ keeps pressure on Keytruda with Imfinzi expansion in chemo-ineligible bladder cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 November 2026 · Fusion42 review
The FDA approved AstraZeneca's Imfinzi combined with Pfizer and Astellas' Padcev as a pre-surgery treatment for cisplatin-ineligible muscle-invasive bladder cancer patients, positioning it as a competitor to Merck's Keytruda-Padcev combo in the US. This approval follows promising trial results showing significant reductions in death and recurrence risks, expanding treatment options for a patient group with limited therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new US pathway to challenge Merck in bladder cancer with a less intensive Imfinzi-Padcev regimen now FDA cleared for cisplatin-ineligible patients. Start refining your market access and customer engagement strategy ahead of EU and Japan moves.
◆ Coverage
1 source · 13 Nov 2026
◆ Related on Wire
◆ Topics